Literature DB >> 23525757

Bronchoscopic findings for bevacizumab-related pulmonary hemorrhage in advanced non-small cell lung cancer.

Kunio Okamoto1, Isamu Okamoto, Masaki Miyazaki, Kaoru Tanaka, Hiroyasu Kaneda, Kazuhiko Nakagawa.   

Abstract

We report contemporaneous bronchoscopic findings for a case of bevacizumab-related pulmonary hemorrhage in a patient with advanced non-small cell lung cancer (NSCLC). Flexible bronchoscopy at diagnosis revealed abnormal capillary dilation that was suggestive of endobronchial involvement at the primary tumor location. The patient developed massive hemoptysis despite of marked tumor shrinkage achieved by bevacizumab-containing chemotherapy. Emergency flexible bronchoscopy for hemoptysis suggested that the location of the primary tumor was the source of bleeding. Subsequent follow-up flexible bronchoscopy revealed an ulcerative mucosal-like lesion associated with a white necrotic substance as well as attenuation of the dilation of submucosal vessels compared with that apparent at diagnosis. Our case report highlights the potential mechanistic insights into bevacizumab-related bleeding and importance of performing bronchoscopy at diagnosis in NSCLC patients, given that abnormal bronchoscopic findings may be a risk factor for bleeding.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23525757     DOI: 10.1007/s10637-013-9951-x

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  8 in total

1.  Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.

Authors:  Isamu Okamoto; Hiroshige Yoshioka; Satoshi Morita; Masahiko Ando; Koji Takeda; Takashi Seto; Nobuyuki Yamamoto; Hideo Saka; Kazuhiro Asami; Tomonori Hirashima; Shinzoh Kudoh; Miyako Satouchi; Norihiko Ikeda; Yasuo Iwamoto; Toshiyuki Sawa; Masaki Miyazaki; Kenji Tamura; Takayasu Kurata; Masahiro Fukuoka; Kazuhiko Nakagawa
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

2.  What is the evidence that tumors are angiogenesis dependent?

Authors:  J Folkman
Journal:  J Natl Cancer Inst       Date:  1990-01-03       Impact factor: 13.506

Review 3.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

Review 4.  Bevacizumab: current updates in treatment.

Authors:  Margaret Em Van Meter; Edward S Kim
Journal:  Curr Opin Oncol       Date:  2010-11       Impact factor: 3.645

5.  Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.

Authors:  Xiao Feng Hang; Wen Sheng Xu; Jun Xue Wang; Lei Wang; Hai Guang Xin; Rui Qi Zhang; Wu Ni
Journal:  Eur J Clin Pharmacol       Date:  2011-01-18       Impact factor: 2.953

6.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

7.  Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.

Authors:  Alan B Sandler; Joan H Schiller; Robert Gray; Isaiah Dimery; Julie Brahmer; Meghna Samant; Lisa I Wang; David H Johnson
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

Review 8.  Mechanisms of adverse effects of anti-VEGF therapy for cancer.

Authors:  T Kamba; D M McDonald
Journal:  Br J Cancer       Date:  2007-05-22       Impact factor: 7.640

  8 in total
  1 in total

1.  Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis.

Authors:  Koichi Goto; Masahiro Endo; Masahiko Kusumoto; Nobuyuki Yamamoto; Yuichiro Ohe; Ayaka Shimizu; Masahiro Fukuoka
Journal:  Cancer Sci       Date:  2016-12-12       Impact factor: 6.716

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.